Oppenheimer initiated coverage of SAB Biotherapeutics (SABS) with an Outperform rating and $12 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
- SAB Biotherapeutics founds Clinical Advisory Board for SAB-142 development
- SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
- SAB Biotherapeutics Announces Key Executive Appointment
- SAB BIO Appoints Lucy To as Chief Financial Officer